Browse > Article
http://dx.doi.org/10.5483/BMBRep.2015.48.2.239

Identification of a novel type of small molecule inhibitor against HIV-1  

Kim, Byung Soo (Avixgen Inc.)
Park, Jung Ae (Avixgen Inc.)
Kim, Min-Jung (Avixgen Inc.)
Kim, Seon Hee (National Research Laboratory of Molecular Virology, Department of Pathology, School of Medicine, The Catholic University of Korea)
Yu, Kyung Lee (National Research Laboratory of Molecular Virology, Department of Pathology, School of Medicine, The Catholic University of Korea)
You, Ji Chang (Avixgen Inc.)
Publication Information
BMB Reports / v.48, no.2, 2015 , pp. 121-126 More about this Journal
Abstract
Here we report a new chemical inhibitor against HIV-1 with a novel structure and mode of action. The inhibitor, designated as A1836, inhibited HIV-1 replication and virus production with a 50% inhibitory concentration ($IC_{50}$) of $2.0{\mu}M$ in an MT-4 cell-based and cytopathic protection antiviral assay, while its 50% cytotoxic concentration ($CC_{50}$) was much higher than $50{\mu}M$. Examination of the effect of A1836 on in vitro HIV-1 reverse transcriptase (RT) and integrase showed that neither were molecular targets of A1836. The characterization and re-infection assay of the HIV-1 virions generated in the presence of A1836 showed that the synthesis of early RT products in the cells infected with the virions was inhibited dose-dependently, due in part to abnormal protein formation within the virions, thus resulting in an impaired infectivity. These results suggest that A1836 might be a novel candidate for the development of a new type of HIV-1 inhibitor.
Keywords
HIV-1 inhibitor; Infectivity; Novel chemical structure; Reverse transcription; Viral protein processing;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Hayashi S, Phadtare S, Zemlicka J, Matsukura M, Mitsuya H and Broder S (1988) Adenallene and cytallene: acyclic- nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A 85, 6127-6131   DOI   ScienceOn
2 Dubé M, Bego MG, Paquay C and Cohen ÉA (2010) Modulation of HIV-1 host interaction: role of the Vpu accessory protein. Retrovirology 7, 144   DOI
3 Li ZY, Zhan P and Liu XY (2010) Progression in the study of HIV-1 Vif and related inhibitors. Yao Xue Xue Bao 45, 684-693
4 Kwon HS, Park JA, Kim JH and You JC (2012) Identification of anti-HIV and anti-reverse transcriptase activity from Tetracera scandens. BMB Rep 45, 165-170   DOI   ScienceOn
5 Forshey BM, von Schwedler U, Sundquist WI and Aiken C (2002) Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol 76, 5667-5677   DOI
6 Srivastava P, Schito M, Fattah RJ et al (2004) Optimization of unique, uncharged thioesters as inhibitors of HIV replication. Bioorg Med Chem 12, 6437-6450   DOI   ScienceOn
7 Ong EB, Watanabe N, Saito A et al (2011) Vipirin, a coumarin-based HIV-1 Vpr inhibitor, interacts with a hydrophobic region of VPR. J Biol Chem 286, 14049-14056   DOI   ScienceOn
8 De Clercq E (1992) HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 8, 119-134   DOI   ScienceOn
9 Molla A, Granneman GR, Sun E and Kempf DJ (1998) Recent developments in HIV protease inhibitor therapy. Antiviral Res 39, 1-23   DOI   ScienceOn
10 Ingale KB and Bhatia MS (2011) HIV-1 integrase inhibitors: a review of their chemical development. Antivir Chem Chemother 22, 95-105   DOI   ScienceOn
11 Ryser HJ and Flückiger R (2005) Progress in targeting HIV-1 entry. Drug Discov Today 10, 1085-1094   DOI   ScienceOn
12 Mehellou Y and De Clercq E (2010) Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem 53, 521-538   DOI   ScienceOn
13 Flexner C (2007) HIV drug development: the next 25 years. Nat Rev Drug Discov 6, 959-966   DOI   ScienceOn
14 Condra JH, Schleif WA, Blahy OM et al (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571   DOI   ScienceOn
15 Freed EO (1998) HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251, 1-15   DOI   ScienceOn
16 Domagala JM, Bader JP, Gogliotti RD et al (1997) A new class of anti-HIV-1 agents targeted toward the nucleocapsid protein NCp7: the 2, 2'-dithiobisbenzamides. Bioorg Med Chem 5, 569-579   DOI   ScienceOn